title: Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders.
authors.forename: Sarojini M
authors.initials: SM
authors.lastname: Sengupta
authors.forename: Ruby
authors.initials: R
authors.lastname: Klink
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Stip
authors.forename: Trino
authors.initials: T
authors.lastname: Baptista
authors.forename: Ashok
authors.initials: A
authors.lastname: Malla
authors.forename: Ridha
authors.initials: R
authors.lastname: Joober
mesh_terms: D000328:Adult; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000378:metabolism*; D008078:Cholesterol, LDL / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced*; D008297:Male; D000077152:Olanzapine; D011446:Prospective Studies; D011618:Psychotic Disorders / Q000188:drug therapy*; D015430:Weight Gain
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D001569:Benzodiazepines; D000077152:Olanzapine